Advantage of recombinant von Willebrand factor for peri-operative management in pediatric acquired von Willebrand syndrome.

Angela C. Weyand¹, Rohith Jesudas², Steven W. Pipe¹,³

1. Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, Michigan
2. Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine, Peoria, Illinois
3. Department of Pathology, University of Michigan, Ann Arbor, Michigan

Corresponding Author:
Angela C. Weyand
1150 W. Medical Center Drive, MSRB III, Room 8346, Ann Arbor, MI 48109.
(734) 764-9336 (phone)
(734) 232-8740 (fax)
acweyand@med.umich.edu

Word Count: 872

Running title: Recombinant vWF in acquired von Willebrand syndrome

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/hae.13436

This article is protected by copyright. All rights reserved
Dear Editors,

A two-year-old African American male child with pulmonary valve stenosis sustained a skull fracture and large epidural hemorrhage after a fall. He underwent multiple procedures over several days, all of which were complicated by post-operative bleeding. Past bleeding history was significant for bleeding with eruption of new teeth. Family history was negative for bleeding manifestations. Laboratory workup prior to a planned cranioplasty revealed normal prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, Factor IX, Factor XI and Factor XIII (present by clot dissolution assay). Blood type was AB+. A von Willebrand factor (vWF) panel revealed elevated Factor VIII (FVIII) of 333%, normal ristocetin cofactor activity (vWF:RCo) of 58% (normal range 50-150%) with vWF antigen (vWF:Ag) of 178% (normal range 50-150%)(Table 1). The vWF:RCo/vWF:Ag ratio was abnormally decreased to 0.33, consistent with acquired von Willebrand syndrome (avWS), likely secondary to pulmonic stenosis. Plasma von Willebrand multimer analysis revealed absence or decreased abundance of the highest molecular weight multimers (HMWM), but no definitely increased abundance of lower molecular weight vWF multimers, more characteristic of avWS than a congenital vWF defect. Although his vWF:RCo level was within a low-normal range, most guidelines suggest attaining a goal activity level of 100 IU/dL[1] for surgical prophylaxis, particularly in major surgery.

Given need for cranioplasty in the setting of avWS and significantly elevated Factor VIII levels, there was concern about the use of traditional plasma-derived vWF concentrates (which all include FVIII in variable proportions) and potential for increased thrombotic risk. Although thrombotic events are rare occurrences in patients with bleeding disorders, the risk in von Willebrand disease (vWD) does seem to be increased compared to that seen in hemophilia[2]. Three of the four vWD patients with thrombotic events within a systematic...
review whose FVIII level was measured had levels in excess of 200%[2]. Given this, most guidelines recommend following FVIII levels with replacement therapy and avoiding levels > 100-200%[1,2]. Thus, the decision was made to treat pre-operatively with a recombinant vWF (rvWF) which does not contain FVIII (Vonvendi®, Shire, Dublin, Ireland) and may confer a lower risk of thromboembolic sequelae. The rvWF (80 IU/kg) was administered just prior to surgery. Adequate hemostasis was achieved with minimal blood loss. There was concern for an acute bleed due to a drop in hemoglobin on post-operative day 2 so he received an additional dose of 80 IU/kg of rvWF. This was later attributed to dilutional effects of intravenous fluid and no evidence of bleeding was found by clinical assessment or imaging. The patient recovered well without complication.

Acquired von Willebrand syndrome is a rare entity with bleeding symptomatology similar to those seen in the inherited form of vWD. It is typically characterized by a negative family history, lack of prior bleeding symptoms, and older age. It most commonly occurs in patients with lymphoproliferative or myeloproliferative disease (63%), cardiovascular disease (21%), solid tumors (5%) or autoimmune disorders (2%). Within cardiovascular disease, where loss of HMWM is caused by increased shear stress, it has been reported to occur with aortic stenosis, pulmonary stenosis, patent ductus arteriosus, ventricular and atrial septal defects, and ventricular assist devices[3]. Risk of bleeding in patients with cardiopulmonary disorders has been associated with a VWF:RCo/VWF:Ag ratio of <0.7[4]. There are no consistent guidelines for the treatment of aVWS likely due to its rarity. The efficacy of DDAVP is likely to be limited and patients with cardiovascular disease have been reported to have the worst outcomes with its use with therapeutic responses only seen in 10%[5]. Additionally, DDAVP provided additional obstacles in our patient given the hemostatic challenges inherent to neurosurgery, his young age and risk of hyponatremia, and concern for further elevation of his FVIII.

Another complicating factor in our patient was his baseline elevation in FVIII, likely secondary to a combination of an acute phase reaction to ongoing inflammation, non-O
blood type [6], and ethnicity [7]. Elevated plasma levels of FVIII have been associated with a dose-dependent increased thrombotic risk at levels >150 IU/dl[8]. At least one case has been reported of avWS with elevated FVIII (to levels similar to our patient) treated with plasma-derived FVIII/vWF concentrate who went on to develop an embolic stroke[9].

Given his severely elevated levels pre-operatively, the use of a plasma-derived FVIII/vWF concentrate was deemed to pose an unacceptable risk in terms of thrombosis.

Recombinant vWF, in addition to the advantage of the absence of FVIII, also includes ultra-large and high molecular weight multimers which are likely to be beneficial in the treatment of avWS. Additionally, most plasma-derived FVIII/vWF concentrates typically have a vWF:RCo/vWF:Ag ratio of <1, as opposed to >1 in rvWF[10]. This is likely to be advantageous in a disease where the vWF: RCo/vWF:Ag ratio is by very definition decreased. This case illustrates an ideal scenario in which rvWF may provide distinct advantages over plasma-derived FVIII/vWF concentrates. This is, to our knowledge, the first report of the use of rvWF in a pediatric patient, as well as the first reported case in avWS, since its approval in 2015. As yet, it has only been approved for on-demand treatment, with prophylactic Phase 3 trials ongoing. Peri-operative treatment in this pediatric patient was efficacious, safe and tolerable. He did not develop any thrombotic complications and no evidence of antibodies to vWF were observed.

Acknowledgements

Declaration of Interest: ACW has served as a consultant for Shire, and serves as a co-investigator on a study funded by Shire. RJ has no conflicts to disclose. SWP has served as a consultant for Shire and CSL Behring.

ACW analysed the data and wrote the paper, RJ and SWP analysed the data and performed critical manuscript review and edits.


